Lupin links with Polish firm to jumpstart Advair generic plans
This article was originally published in Scrip
Executive Summary
Lupin has unveiled plans for a significant step up in the inhalation therapy segment, with back-to-back announcements on its efforts for a generic version of GlaxoSmithKline's blockbuster asthma/COPD product, Advair/Seretide (salmeterol/fluticasone), and the launch in the US of a device to enhance delivery of aerosol therapies.
You may also be interested in...
Lupin’s US Advair Generic Plans Turn Awry As Celon Pact Nears End
Lupin’s plans for a US generic to GSK’s Advair Diskus have turned awry as its contract with Celon Pharma is close to being terminated. The company has focused on other respiratory drugs like generic ProAir and Fostair even as the revenue potential for Advair has been shrinking post Mylan’s launch.
Lupin’s US Advair Generic Plans Turn Awry As Celon Pact Nears End
Lupin’s plans for a US generic to GSK’s Advair Diskus have turned awry as its contract with Celon Pharma is close to being terminated. The company has focused on other respiratory drugs like generic ProAir and Fostair even as the revenue potential for Advair has been shrinking post Mylan’s launch.
Glenmark-Celon Generic Seretide DPI On Its Way In Europe
Glenmark-Celon’s generic Seretide Accuhaler dry powder inhaler (DPI) appears on course for a debut in Europe, piling up more pressure on GlaxoSmithKline’s respiratory franchise. Substitutability of the generic, however, will be key to driving momentum in uptake.